•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A06987 Summary:

BILL NOA06987A
 
SAME ASNo Same As
 
SPONSORSeptimo
 
COSPNSRAlvarez, Tapia, Griffin, Bichotte Hermelyn, Reyes, Yeger, Hevesi
 
MLTSPNSR
 
Add §280-e, Pub Health L
 
Requires covered entities report to the department of health regarding certain 340B drug discounts and what percentage of patients benefit from such discounts.
Go to top

A06987 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                         6987--A
 
                               2025-2026 Regular Sessions
 
                   IN ASSEMBLY
 
                                     March 18, 2025
                                       ___________
 
        Introduced by M. of A. SEPTIMO, ALVAREZ, TAPIA, GRIFFIN, BICHOTTE HERME-
          LYN,  REYES,  YEGER, HEVESI -- read once and referred to the Committee
          on Health -- recommitted to the Committee on Health in accordance with
          Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered
          reprinted as amended and recommitted to said committee

        AN ACT to amend the public health law, in relation to  requiring  trans-
          parency requirements for certain 340B drugs
 
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
 
     1    Section 1. The public health law is amended by adding  a  new  section
     2  280-e to read as follows:
     3    § 280-e. Accountability to safeguard benefits for vulnerable patients.
     4  1.  For the purposes of this section, the following terms shall have the
     5  following meanings:
     6    (a) "340B drug" shall mean a covered outpatient drug, as defined by 42
     7  USC § 1396r-8(k)(2), that has been subject  to  any  offer  for  reduced
     8  prices  by  a  manufacturer  pursuant  to  42  USC  § 256b(a)(1), and is
     9  purchased by a covered entity.
    10    (b) "340B  profits"  shall  mean  the  difference  between  aggregated
    11  payments received from insurers, payors, or self-paying patients for all
    12  340B drugs and the aggregate acquisition cost pay for all 340B drugs.
    13    (c)  "340B  program"  shall  mean  the  federal  drug  pricing program
    14  described in 42 USC § 256b.
    15    (d) "Charity care" shall have the same meaning  as  ascribed  to  such
    16  term  as  is  found in line twenty-three of the S-10 Medicare cost work-
    17  sheet or any successor form.
    18    (e) "Contract pharmacy" shall mean a pharmacy  with  which  a  covered
    19  entity  has  contracted to dispense 340B drugs on behalf of such covered
    20  entity to patients  of  such  covered  entity,  whether  distributed  in
    21  person, via mail, or by other means.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD10744-02-6

        A. 6987--A                          2
 
     1    (f)  "Covered  entity"  shall  have the same meaning as under 42 USC §
     2  256b(a)(4).  Provided, however, a covered entity  shall  not  include  a
     3  federally qualified health center.
     4    (g) "Low-income patient" shall mean a patient of a covered entity with
     5  a  family income below two hundred percent of the federal poverty guide-
     6  lines.
     7    2. Beginning April first,  two  thousand  twenty-seven,  each  covered
     8  entity shall report to the department with respect to such covered enti-
     9  ty  and  separately for each offsite outpatient facility associated with
    10  such covered entity, in a form and manner as determined by  the  depart-
    11  ment, the following information about the prior year:
    12    (a)  Delineated  by form of insurance or payor type, including but not
    13  limited to Medicaid, Medicare, commercial insurance,  and  uninsured  to
    14  include:
    15    (i) aggregated acquisition costs paid for all 340B drugs;
    16    (ii) aggregated payments received from insurers, payors, and self-pay-
    17  ing patients for all 340B drugs;
    18    (iii)  the total number of prescriptions and percentage of the covered
    19  entity's prescriptions that were filled with 340B drugs; and
    20    (iv) the percentage of patients served by a sliding fee scale for 340B
    21  drugs at the point of sale for low-income patients.
    22    (b) The total operating costs for such covered  entity,  and  itemized
    23  costs for:
    24    (i)  implementing  direct  pass through of 340B profits to patients in
    25  the form of lower cost sharing for 340B drugs at the point of dispensing
    26  or administration;
    27    (ii) implementing a sliding fee scale for 340B drugs at the  point  of
    28  sale for low-income patients; and
    29    (iii) charity care.
    30    (c) The total payments made to:
    31    (i)  contract  pharmacies  for 340B program related services and other
    32  functions;
    33    (ii) third-party administrators for managing any  components  of  such
    34  covered entity's 340B program; and
    35    (iii)  any other third parties in connection with 340B program-related
    36  compliance, legal, educational, and/or administrative costs.
    37    (d) The total number of contract pharmacies, including:
    38    (i) the number of contract pharmacies  located  out-of-state  and  the
    39  states in which such out-of-state pharmacies are located;
    40    (ii)  the  total  number  of  prescriptions  and the percentage of the
    41  covered entity's prescriptions that were filled at contract  pharmacies,
    42  delineated by in-state and out-of-state contract pharmacies;
    43    (iii)  the  total remuneration paid to or retained by contract pharma-
    44  cies or their affiliates for any 340B program-related services performed
    45  on behalf of the covered entity; and
    46    (iv) the percentage change in total remuneration paid to  or  retained
    47  by  contract pharmacies or their affiliates as described in subparagraph
    48  (iii) of this paragraph compared to the prior year.
    49    3. An officer of a covered entity shall certify the  completeness  and
    50  accuracy  of  the  report  submitted pursuant to subdivision two of this
    51  section.
    52    4. The department shall post all reports submitted by covered entities
    53  pursuant to subdivision two of this section  on  a  publicly  accessible
    54  website.
    55    § 2. This act shall take effect immediately.
Go to top